Demographic and clinical data at baseline
| Patients, n Swedish/Norwegian | 104 (69/35) |
| Gender, female/male | 76/28 |
| Age, years (mean/range) | 30 /(10-58) |
| Disease duration, years (mean) | 5.8 |
| EDSS at baseline (median/range) | 3/(0–6.5) |
| No of previous treatments | 2.1 (0–6) |
| Last treatment (≤6 months prior to HSCT) | |
| No treatment | 25 (24%) |
| Standard DMT | |
| Interferons | 6 (6%) |
| Glatiramer acetate | 4 (4%) |
| Fingolimod | 15 (14%) |
| Natalizumab | 20 (19%) |
| Dimethyl fumarate | 5 (5%) |
| Teriflunomide | 3 (3%) |
| DMT with long-lasting effect | |
| Alemtuzumab | 6 (6%) |
| Cladribine | 2 (2%) |
| Rituximab | 18 (17 %) |
DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; HSCT, haematopoietic stem cell transplantation.